Tag Archives: Carl Byrnes

GW Pharma (GWPH) Received its Third Buy in a Row

After Oppenheimer and Needham gave GW Pharma (NASDAQ: GWPH) a Buy rating last month, the company received another Buy, this time from Northland Securities. Analyst Carl Byrnes assigned a Buy rating to GW Pharma today and set a price target

Esperion (ESPR) Receives a Hold from Northland Securities

Northland Securities analyst Carl Byrnes maintained a Hold rating on Esperion (ESPR – Research Report) today and set a price target of $42.00. The company’s shares closed last Wednesday at $40.60. According to TipRanks.com, Byrnes has 0 stars on 0-5

Northland Securities Remains a Buy on Opiant Pharmaceuticals (OPNT)

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Opiant Pharmaceuticals (OPNT – Research Report), with a price target of $42.00. The company’s shares closed last Thursday at $11.78. According to TipRanks.com, Byrnes is

Northland Securities Reaffirms Their Buy Rating on Zogenix (ZGNX)

Northland Securities analyst Carl Byrnes maintained a Buy rating on Zogenix (ZGNX – Research Report) today and set a price target of $65.00. The company’s shares closed last Wednesday at $25.99. According to TipRanks.com, Byrnes has currently no stars on

Northland Securities Keeps a Hold Rating on Esperion (ESPR)

Northland Securities analyst Carl Byrnes maintained a Hold rating on Esperion (ESPR – Research Report) today and set a price target of $42.00. The company’s shares closed last Wednesday at $34.42. According to TipRanks.com, Byrnes has 0 stars on 0-5

Analysts Offer Insights on Healthcare Companies: PolarityTE (NASDAQ: PTE) and Atricure (NASDAQ: ATRC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PolarityTE (PTE – Research Report) and Atricure (ATRC – Research Report) with bullish sentiments. PolarityTE (PTE) Northland Securities analyst Carl Byrnes maintained